Central Pennsylvania Transplant Foundation Incorporated
Central Pennsylvania Transplant Foundation Incorporated
Want to make a donation using Daffy?
Lower your income taxes with a charitable deduction this year when you donate to this non-profit via Daffy.
Do you work for Central Pennsylvania Transplant Foundation Incorporated? Learn more here.
About this organization
Revenue
$37,224
Expenses
$65,020
Mission
TO PROMOTE AND FOSTER ADVANCES IN TRANSPLANTATION THRU ACTIVITIES THAT HAVE INCLUDED PARTICIPATION IN CLINICAL TRIALS INVESTIGATING DIFFERENT IMMUNOSUPPRESSIVE REGIMENS, DEVELOPMENT OF CLINICAL PATHWAYS TO ENHANCE PATIENT CARE, FORUMS FOR PUBLIC AND PHYSICIAN EDUCATION IN TRANSPLANTA- TION, STUDIES RELATED TO OUTCOMES RESEARCH, LABORATORY WORK IN IMMUNOBIOLOGY AND NEW CONCEPTS IN DIABETES MANAGEMENT.
About
1.BRISTOL-MYERS SQUIBB PROTOCOL IM103-116: "EVALUATION OF THE BENEFITS AND RISKS IN MAINTENANCE RENAL TRANSPLANT RECIPIENTS FOLLOWING CONVERSION TO NULOJIX (BELATACEPT)-BASED IMMUNOSUPPRESSION-; PRINCIPAL INVESTIGATOR: HAROLD YANG MD PHD; JUNE 2013-STUDY COMPLETED IN 2019. 2.BRISTOL-MYERS SQUIBB PROTOCOL IM103-177: "EVALUATION OF ACUTE REJECTION RATES IN DE NOVO RENAL TRANSPLANT RECIPIENTS FOLLOWING THYMOGLOBULIN INDUCTION, CNI-FREE, NULOJIX (BELATACEPT)-BASED IMMUNOSUPPRESSION-; PRINCIPAL INVESTIGATOR: HAROLD YANG MD PHD; APRIL 2014-STUDY COMPLETED IN 2019. 3.NOVARTIS PROTOCOL CRAD001A2433: A 24 MONTH, MULTICENTER, RANDOMIZED, OPEN-LABEL SAFETY AND EFFICACY STUDY OF CONCENTRATION-CONTROLLED EVEROLIMUS WITH REDUCED CALCINEURIN INHIBITOR VS.MYCOPHENOLATE WITH STANDARD CALCINEURIN INHIBITOR IN DE NOVO RENAL TRANSPLANTATION- ADVANCING RENAL TRANSPLANT EFFICACY AND SAFETY OUTCOMES WITH AN EVEROLIMUS-BASED REGIMEN (TRANSFORM); PRINCIPAL INVESTIGATOR: MARY WAYBILL MD; APRIL 2014- STUDY COMPLETED IN 2019. 4. ALBERTA TRANSPLANT APPLIED GENOMICS CENTRE:DIAGNOSTIC AND THERAPEUTIC APPLICATIONS OF MICROAARAYS IN ORGAN TRANSPLANTATION AND NATIVE ORGAN DISEASES: USING MICROARRAYS TO ASSESS TRANSPLANT BIOPSIES: THE FUTURE STANDARD OF CARE (INTERCOMEX: THE INTERCOM EXTENSION STUDY); SEPTEMBER 2015-STUDY COMPLETED IN 2019. 5.ASTELLAS7163-CL-3201:"A PHASE 2A, RANDOMIZED, OPEN-LABEL, ACTIVE CONTROL, MULTI-CENTER STUDY TO ASSESS THE EFFICACY AND SAFETY OF BLESELUMAB IN PREVENTING THE RECURRENCE OF FOCAL SEGMENTAL GLOMERULOSCEROSIS IN DE NOVO KIDNEY TRANSPLANT RECIPIENTS-; FEBRUARY 2017-PRESENT. STUDY ACTIVE. 6. VITAERIS PROTOCOL VKTX01 "A PIVOTAL PHASE 3 TRIAL TO EVALUATE THE SAFETY AND EFFICACY OF CLAZAKIZUMAB FOR THE TREATMENT OF CHRONIC ACTIVE-MEDICATED REJECTION IN KIDNEY TRANSPLANT RECIPIENTS". APRIL 2019-PRESENT. 7. USE OF HEPATITIS C POSITIVE DECEASED DONOR KIDNEYS FOR TRANSPLANTATION IN PATIENTS THAT ARE HEPATITIS C NEGATIVE; SEPTEMBER 2019-PRESENT. 8. EVALUATION OF POST-TRANSPLANT MALIGNANCIES: A RETROSPECTIVE ANALYSIS OF UPMC PINNACLE TRANSPLANT PATIENTS UNDERGOING RENAL TRANSPLANT 200-2019 WHO DEVELOPED MALIGNANCIES. 9. EVALUATION OF POST-OPERATIVE OPIATE PAIN MEDICATIONS (IV>PO) IN LIVING KIDNEY DONORS IS ASSOCIATED WITH INCREASED LENGTH-OF-STAY. "A RETROSPECTIVE ANALYSIS OF PATIENTS UNDERGOING LIVING DONOR NEPHRECTOMY AT UPMC PINNACLE FROM JANUARY 2014 TO MARCH 2020. 10. EFFECT OF INDUCTION AND MYCOPHENOLIC-ACID THERAPEUTIC DRUG MONITORING ON DEVELOPMENT OF LEUKOPENIA FOLLOWING KIDNEY TRANSPLANTATION. "A RETROSPECTIVE CHART REVIEW OF ADULT RENAL TRANSPLANT PATIENTS AT UPMC PINNACLE FROM MARCH 2016 TO MARCH 2019.
Interesting data from their 2020 990 filing
The purpose of the non-profit is outlined in the filing as “To promote and foster advances in transplantation thru activities that have included participation in clinical trials investigating different immunosuppressive regimens, development of clinical pathways to enhance patient care, forums for public and physician education in transplanta- tion, studies related to outcomes research, laboratory work in immunobiology and new concepts in diabetes management.”.
When discussing its operations, they were defined as: “To promote and foster advances in transplantation thru activities that have included participation in clinical trials investigating different immunosuppressive regimens, development of clinical pathways to enhance patient care, forums for public and physician education in transplanta- tion, studies related to outcomes research, laboratory work in immunobiology and new concepts in diabetes management.”.
- The non-profit has reported 0 employees on their form as of 2020.
- Does not operate a hospital.
- Does not operate a school.
- Does not collect art.
- Does not provide credit counseling.
- Does not have foreign activities.
- Is not a donor-advised fund.
- Is not a private foundation.
- Expenses are less than $100,000.
- Revenue is less than $100,000.
- Revenue less expenses is -$27,796.
- The CEO compensation structure within the organization is not based on a review and approval from an impartial entity.
- The organization has 2 independent voting members.
- The organization pays $0 in salary, compensation, and benefits to its employees.
- The organization pays $0 in fundraising expenses.
- The organization has minutes of its meetings.
Additional Non-Profits in the area
By donating on this page you are making an irrevocable contribution to Daffy Charitable Fund, a 501(c)(3) public charity, and a subsequent donation recommendation to the charity listed above, subject to our Member Agreement. Contributions are generally eligible for a charitable tax-deduction and a yearly consolidated receipt will be provided by Daffy. Processing fees may be applied and will reduce the value available to send to the end charity. The recipient organizations have not provided permission for this listing and have not reviewed the content.
Donations to organizations are distributed as soon as the donation is approved and the funds are available. In the rare event that Daffy is unable to fulfill the donation request to this charity, you will be notified and given the opportunity to choose another charity. This may occur if the charity is unresponsive or if the charity is no longer in good standing with regulatory authorities.